Cargando…
The Role of Inositol in Thyroid Physiology and in Subclinical Hypothyroidism Management
Myo-Inositol (MYO) is the most abundant stereoisomer of inositols’ family, cyclic polyols with 6 hydroxyl groups. Myo-Inositol has a relevant role in thyroid function and autoimmune diseases, as a precursor of phosphoinositides that takes part in the phosphatidylinositol (PI) signal transduction pat...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143049/ https://www.ncbi.nlm.nih.gov/pubmed/34040582 http://dx.doi.org/10.3389/fendo.2021.662582 |
_version_ | 1783696674514796544 |
---|---|
author | Benvenga, Salvatore Nordio, Maurizio Laganà, Antonio Simone Unfer, Vittorio |
author_facet | Benvenga, Salvatore Nordio, Maurizio Laganà, Antonio Simone Unfer, Vittorio |
author_sort | Benvenga, Salvatore |
collection | PubMed |
description | Myo-Inositol (MYO) is the most abundant stereoisomer of inositols’ family, cyclic polyols with 6 hydroxyl groups. Myo-Inositol has a relevant role in thyroid function and autoimmune diseases, as a precursor of phosphoinositides that takes part in the phosphatidylinositol (PI) signal transduction pathway. Among phosphoinositides, phosphatidylinositol 4,5- bisphosphate (PIP2) is the precursor of inositol triphosphates (IP3), second messenger of several hormones including thyroid-stimulating hormone (TSH). As a second messenger in the phospholipase C (PLC)-dependent inositol phosphate Ca(2+)/DAG pathway, Myo-Inositol is essential to produce H(2)O(2) required for the synthesis of thyroid hormones. Consequently, depletion of Myo-Inositol or impaired inositol dependent TSH signaling pathway may predispose to the development of some thyroid diseases, such as hypothyroidism. Many clinical studies have shown that after treatment with Myo-Inositol plus Selenium (MYO+Se), TSH levels significantly decreased in patients with subclinical hypothyroidism with or without autoimmune thyroiditis. The TSH reduction was accompanied by a decline of antithyroid autoantibodies. Moreover, Myo-Inositol supplementation seemed to be involved also in the management of thyroidal benign nodules, with a possible effect in the size reduction. This review proposes a summary of the role of inositol, especially of Myo-Inositol, in the thyroidal physiology and its contribution on the management of some thyroid diseases. |
format | Online Article Text |
id | pubmed-8143049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81430492021-05-25 The Role of Inositol in Thyroid Physiology and in Subclinical Hypothyroidism Management Benvenga, Salvatore Nordio, Maurizio Laganà, Antonio Simone Unfer, Vittorio Front Endocrinol (Lausanne) Endocrinology Myo-Inositol (MYO) is the most abundant stereoisomer of inositols’ family, cyclic polyols with 6 hydroxyl groups. Myo-Inositol has a relevant role in thyroid function and autoimmune diseases, as a precursor of phosphoinositides that takes part in the phosphatidylinositol (PI) signal transduction pathway. Among phosphoinositides, phosphatidylinositol 4,5- bisphosphate (PIP2) is the precursor of inositol triphosphates (IP3), second messenger of several hormones including thyroid-stimulating hormone (TSH). As a second messenger in the phospholipase C (PLC)-dependent inositol phosphate Ca(2+)/DAG pathway, Myo-Inositol is essential to produce H(2)O(2) required for the synthesis of thyroid hormones. Consequently, depletion of Myo-Inositol or impaired inositol dependent TSH signaling pathway may predispose to the development of some thyroid diseases, such as hypothyroidism. Many clinical studies have shown that after treatment with Myo-Inositol plus Selenium (MYO+Se), TSH levels significantly decreased in patients with subclinical hypothyroidism with or without autoimmune thyroiditis. The TSH reduction was accompanied by a decline of antithyroid autoantibodies. Moreover, Myo-Inositol supplementation seemed to be involved also in the management of thyroidal benign nodules, with a possible effect in the size reduction. This review proposes a summary of the role of inositol, especially of Myo-Inositol, in the thyroidal physiology and its contribution on the management of some thyroid diseases. Frontiers Media S.A. 2021-05-10 /pmc/articles/PMC8143049/ /pubmed/34040582 http://dx.doi.org/10.3389/fendo.2021.662582 Text en Copyright © 2021 Benvenga, Nordio, Laganà and Unfer https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Benvenga, Salvatore Nordio, Maurizio Laganà, Antonio Simone Unfer, Vittorio The Role of Inositol in Thyroid Physiology and in Subclinical Hypothyroidism Management |
title | The Role of Inositol in Thyroid Physiology and in Subclinical Hypothyroidism Management |
title_full | The Role of Inositol in Thyroid Physiology and in Subclinical Hypothyroidism Management |
title_fullStr | The Role of Inositol in Thyroid Physiology and in Subclinical Hypothyroidism Management |
title_full_unstemmed | The Role of Inositol in Thyroid Physiology and in Subclinical Hypothyroidism Management |
title_short | The Role of Inositol in Thyroid Physiology and in Subclinical Hypothyroidism Management |
title_sort | role of inositol in thyroid physiology and in subclinical hypothyroidism management |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143049/ https://www.ncbi.nlm.nih.gov/pubmed/34040582 http://dx.doi.org/10.3389/fendo.2021.662582 |
work_keys_str_mv | AT benvengasalvatore theroleofinositolinthyroidphysiologyandinsubclinicalhypothyroidismmanagement AT nordiomaurizio theroleofinositolinthyroidphysiologyandinsubclinicalhypothyroidismmanagement AT laganaantoniosimone theroleofinositolinthyroidphysiologyandinsubclinicalhypothyroidismmanagement AT unfervittorio theroleofinositolinthyroidphysiologyandinsubclinicalhypothyroidismmanagement AT benvengasalvatore roleofinositolinthyroidphysiologyandinsubclinicalhypothyroidismmanagement AT nordiomaurizio roleofinositolinthyroidphysiologyandinsubclinicalhypothyroidismmanagement AT laganaantoniosimone roleofinositolinthyroidphysiologyandinsubclinicalhypothyroidismmanagement AT unfervittorio roleofinositolinthyroidphysiologyandinsubclinicalhypothyroidismmanagement |